甘李药业：签订30亿元供应框架协议

Core Viewpoint - The company has signed a technology transfer and supply agreement with Fundação Oswaldo Cruz-Bio-Manguinhos and BIOMM, which is expected to positively impact its operating performance in 2025 and beyond [1] Group 1: Agreements and Financial Implications - The technology transfer agreement involves the transfer of insulin technology and the supply of active pharmaceutical ingredients and injectable solutions [1] - The total amount of the supply framework agreement is expected to be no less than RMB 3 billion, with the final amount based on actual orders [1] - The signing of these contracts has been approved within the company's general manager's authority and has followed internal approval procedures [1] Group 2: Future Impact - The execution of these contracts is anticipated to enhance the company's overall profitability [1] - The agreements are expected to have a positive effect on the company's operating performance in 2025 and subsequent years [1]